'Malignancy' in meningiomas: A clinicopathologic study of 116 patients, with grading implications

Cancer

Volumn 85, Issue 9, 1999, Pages 2046-2056

  Perry, Arie ^a   Scheithauer, Bernd W ^b   Stafford, Scott L ^b   Lohse, Christine M ^b   Wollan, Peter C ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Anaplasia; Ki 67; Malignant tumor; Meningioma; Metastasis; MIB 1; Mitotic index; Neoplasm invasiveness; Prognosis; Tumor recurrence

Indexed keywords

KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67;

ADOLESCENT; ADULT; AGED; ANAPLASTIC CARCINOMA; ARTICLE; BRAIN METASTASIS; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MALIGNANT MENINGIOMA; MITOSIS INDEX; NEUROPATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; HUMANS; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; MITOSIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0033134921     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990501)85:9<2046::AID-CNCR23>3.0.CO;2-M     Document Type: Article

References (69)

1. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol 1997;21:1455-65.
2. Hsu DW, Pardo FS, Efird JT, Linggood RM, Hedley-Whyte ET. Prognostic significance of proliferative indices in meningiomas. J Neuropathol Exp Neurol 1994;53:247-55.
3. Yao Y-T. Clinicopathologic analysis of 615 cases of meningioma with special reference to recurrence. J Formosa Med Assoc 1994;93:145-52.
4. Miller DC. Predicting recurrence of intracranial meningiomas: a multivariate clinicopathologic model - interim report of the New York University Medical Center meningioma project. Neurosurg Clin North Am 1994;5:193-200.
5. Mahmood A, Caccamo DV, Tomecek FJ, Malik GM. Atypical and malignant meningiomas: a clinicopathological review. Neurosurgery 1993;33:955-63.
6. McLean CA, Jolley D, Cukier E, Giles G, Gonzales MF. Atypical and malignant meningiomas: importance of micronecrosis as a prognostic indicator. Histopathology 1993;23: 349-53.
7. Maier H, Öfner D, Hittmair A, Kitz K, Budka H. Classic, atypical, and anaplastic meningioma: three histopathological subtypes of clinical relevance. J Neurosurg 1992;77:616-23.
8. Chen WYK, Liu HC. Atypical (anaplastic) meningioma: relationship between histologic features and recurrence - a clinicopathologic study. Clin Neuropathol 1990; 9(2):74-81.
9. Rohringer M, Sutherland GR, Louw DF, Sima AAF. Incidence and clinicopathological features of meningioma. J Neurosurg 1989;71:665-72.
10. Jääskeläinen J, Haltia M, Servo A. Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol 1986;25:233-42.
11. de la Monte SM, Flickinger J, Linggood RM. Histopathologic features predicting recurrence of meningiomas following subtotal resection. Am J Surg Pathol 1986;10:836-43.
12. Böker D-K, Meurer H, Gullotta F. Recurring intracranial meningiomas: evaluation of some factors predisposing for tumor recurrence. J Neurosurg Sci 1985;29:11-7.
13. Jellinger K, Slowik F. Histological subtypes and prognostic problems in meningiomas. J Neurol 1975;208:279-98.
14. Skullerud K, Löken AC. The prognosis in meningiomas. Acta Neuropathol (Berlin) 1974;29:337-44.
15. Cushing H, Eisenhardt L. Meningiomas. Their classification, regional behaviour, life history, and surgical end results. Springfield, IL: Charles C. Thomas Publishers, 1938.
16. Russell DS, Rubinstein LJ. Pathology of tumours of the nervous system. 5th ed. Baltimore: Williams & Wilkins, 1989.
17. Burger PC, Scheithauer BW, Vogel FS. Surgical pathology of the nervous system and its coverings. 3rd ed. New York: Churchill Livingstone, 1991.
18. Burger PC, Scheithauer BW. Tumors of the central nervous system. In: Atlas of tumor pathology, 3rd series. Juan Rosai, ed. Washington, DC: Armed Forces Institute of Pathology, 1994.
19. Kleihues P, Burger PC, Scheithauer BW. Histological typing of tumours of the central nervous system. 2nd ed. Berlin: Springer-Verlag, 1993:28-31.
20. Perry A, Scheithauer BW, Stafford SL, Abell-Aleff PC, Meyer FB. "Rhabdoid" meningioma: an aggressive variant. Am J Surg Pathol 1998;22:1482-90.
21. Kepes JJ, Moral LA, Wilkinson SB, Abdullah A, Llena JF. Rhabdoid transformation of tumor cells in meningiomas: a histologic indication of increased proliferative activity. Report of four cases. Am J Surg Pathol 1998;22:231-8.
22. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas. Cancer 1998;82:2262-9.
23. Perry A, Scheithauer BW, Nascimento AG. The immunophenotypic spectrum of meningeal hemangiopericytoma: a comparison with fibrous meningioma and solitary fibrous tumor of meninges. Am J Surg Pathol 1997;21:1354-60.
24. Probst-Cousin S, Bergmann M, Schröder R, Kuchelmeister K, Schmid KW, Ernestus RJ, Janus J. Ki-67 and biological behaviour in meningeal haemangiopericytomas. Histopathology 1996;29:57-61.
25. Renshaw AA, Paulus W, Joseph JT. CD34 and epithelial membrane antigen distinguish dural hemangiopericytoma and meningioma. Appl Immunohistochem 1995;3: 108-14.
26. Molnar P, Nemes Z. Hemangiopericytoma of the cerebellopontine angle. Diagnostic pitfalls and the diagnostic value of the subunit A of factor XIII as a tumor marker. Clin Neuropathol 1995;14:19-24.
27. Nemes Z. Differentiation markers in hemangiopericytoma. Cancer 1992;69:133-40.
28. Winek RR, Scheithauer BW, Wick MR. Meningioma, meningeal hemangiopericytoma (angioblastic meningioma), peripheral hemangiopericytoma, and acoustic schwannoma. A comparative immunohistochemical study. Am J Surg Pathol 1989;13:251-61.
29. Kepes JJ. Meningiomas. Biology, pathology, and differential diagnosis. Masson monographs in diagnostic pathology. Stephen S. Sternberg, ed. New York: Masson, 1982:123,150-182.
30. Weber RG, Boström J, Wolter M, Baudis M, Collins VP, Reifenberger G, et al. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci USA 1997;94:14719-24.
31. Menon AG, Rutter JL, von Sattel JP, Synder H, Murdoch C, Blumenfeld A, et al. Frequent loss of chromosome 14 in atypical and malignant meningioma: identification of a putative 'tumor progression' locus. Oncogene 1997;14: 611-16.
32. Niedermayer I, Feiden W, Henn W, Steilen-Gimbel H. Steudel W-I, Zang KD. Loss of alkaline phosphatase activity in meningiomas: a rapid histochemical technique indicating progression-associated deletion of a putative tumor suppressor gene on the distal part of the short arm of chromosome 1. J Neuropathol Exp Neurol 1997;56(8): 879-86.
33. Tse JYM, Ng H-K, Lau K-M, Lo K-W, Poon W-S, Huang DP. Loss of heterozygosity of chromosome 14q in low-and high-grade meningiomas. Hum Pathol 1997;28:779-85.
34. Perry A, Jenkins RB, Dahl RJ, Moertel CA, Scheithauer BW. Cytogenetic analysis of aggressive meningiomas. Possible diagnostic and prognostic implications. Cancer 1996;77: 2567-73.
35. Deprez RHL, Riegman PH, van Drunen E, Warringa UL, Groen NA, Stefanko SZ, et al. Cytogenetic, molecular genetic and pathological analyses in 126 meningiomas. J Neuropathol Exp Neurol 1995;54:224-35.
36. Simon M, von Deimling A, Larson JJ, Wellenreuther R, Kaskel P, Waha A, et al. Allelic losses on chromosomes 14, 10 and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression. Cancer Res 1995;55: 4696-701.
37. Schneider BF, Shashi V, von Kap-herr C, Golden WL. Loss of chromosomes 22 and 14 in the malignant progression of meningiomas. A comparative study of fluorescence in situ hybridization (FISH) and standard cytogenetic analysis. Cancer Genet Cytogenet 1995;85:101-4.
38. Rempel SA, Schwechheimer K, Davis RL, Cavenee WK, Rosenblum ML. Loss of heterozygosity for loci on chromosome 10 is associated with morphologically malignant meningioma progression. Cancer Res 1993;3:2386-92.
39. Enam SA, Abdulrauf S, Mehta B, Malik GM, Mahmood A. Metastasis in meningioma. Acta Neurochir (Wein) 1996;138: 1172-8.
40. Ng THK, Wong MP, Chan KW. Benign metastasizing meningioma. Clin Neurol Neurosurg 1990;92:152-4.
41. Som PM, Sacher M, Strenger SW, Biller HF, Malis LI. "Benign" metastasizing meningiomas. Am J Neuroradiol 1987; 8:127-30.
42. Miller DC, Ojemann RG, Proppe KH, McGinnis BD, Grillo HC. Benign metastasizing meningioma. Case report. J Neurosurg 1985;62:763-6.
43. Prayson RA. Malignant meningioma. A clinicopathologic study of 23 patients including MIB1 and p53 immunohistochemistry. Am J Clin Pathol 1996;105:719-26.
44. Strang RR, Tovi D, Nordenstam H. Meningioma with intracerebral, cerebellar and visceral metastases. J Neurosurg 1964;21:1098-102.
45. Stangl AP, Wellenreuther R, Lenartz D, Kraus JA, Menon AG, Schramm J, et al. Clonality of multiple meningiomas. J Neurosurg 1997;86:853-8.
46. Pasquier B, Gasnier F, Pasquier D, Keddari E, Morens A, Couderc P. Papillary meningioma. Clinicopathologic study of seven cases and review of the literature. Cancer 1986;58: 299-305.
47. Ludwin SK, Rubinstein LJ, Russell DS. Papillary meningioma: a malignant variant of meningioma. Cancer 1975;36: 1363-73.
48. Zorludemir S, Scheithauer BW, Hirose T, Van Houten C, Miller G, Meyer FB. Clear cell meningioma. A clinicopathologic study of a potentially aggressive variant of meningioma. Am J Surg Pathol 1995;19:493-505.
49. Mahmood A, Qureshi NH, Malik GM. Intracranial meningiomas: analysis of recurrence after surgical treatment. Acta Neurochir (Wein) 1994;126:53-8.
50. Kallio M, Sankila R, Hakulinen T, Jääskeläinen J. Factors affecting operative and excess long-term mortality in 935 patients with intracranial meningioma. Neurosurgery 1992; 31:2-12.
51. Sankila R, Kallio M, Jääskeläinen J, Hakulinen T. Long-term survival of 1986 patients with intracranial meningioma diagnosed from 1953 to 1984 in Finland. Comparison of the observed and expected survival rates in a population-based series. Cancer 1992;70:1568-76.
52. Jääskeläinen J. Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis. Surg Neurol 1986;26:461-9.
53. Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuza RL. Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg 1985;62:18-24.
54. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatr 1957; 20:22-39.
55. Milosevic MF, Frost PJ, Laperriere NJ, Wong CS, Simpson WJ. Radiotherapy for atypical or malignant intracranial meningioma. Int J Radiat Oncol Biol Phys 1996;34:817-22.
56. Akeyson EW, McCutcheon IE. Management of benign and aggressive intracranial meningiomas. Oncology 1996;10: 747-59.
57. Wilson CB. Meningiomas: genetics, malignancy, and the role of radiation in induction and treatment. The Richard C. Schneider lecture. J. Neurosurg 1994;81:666-75.
58. Goldsmith BJ, Wara WM, Wilson CB, Larson DA. Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg 1994;80:195-201.
59. Glaholm J, Bloom HJG, Crow JH. The role of radiotherapy in the management of intracranial meningiomas: the Royal Marsden Hospital experience with 186 patients. Int J Radiat Oncol Biol Phys 1990;18:755-61.
60. Stafford SL, Perry A, Suman V, Meyer FB, Scheithauer BW, Shaw EG, et al. Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978-1988. Mayo Clin Proc 1998;73:936-42.
61. Stafford SL, Perry A, Leavitt JA, Garrity JA, Suman V, Scheithauer BW, et al. Anterior visual pathway meningiomas primarily resected between 1978-1988. The Mayo Clinic experience. J Clin Neuro-Opthalmol 1998;18:206-10.
62. Schrell UMH, Rittig MG, Anders M, Koch UH, Marschalek R, Kiesewetter F, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg 1997;86:840-4.
63. Kaba SE, DeMonte F, Bruner JM, Kyritsis AP, Jaeckle KA, Levin V, et al. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery 1997;40:271-5.
64. De Monte F. Current management of meningiomas. Oncology 1995;9:83-101.
65. Grunberg SM. Role of antiprogestational therapy for meningiomas. Hum Reprod 1994;9(Suppl):202-7.
66. Goodwin JW, Crowley J, Eyre HJ, Stafford B, Jaeckle KA, Townsend JJ. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neuro-Oncol 1993;15:75-7.
67. Lamberts SW, Tanghe HL, Avezaat CJ, Braakman R, Wijngaarde R, Koper JW, et al. Mifepristone (RU 486) treatment of meningiomas. J Neurol Neurosurg Psychol 1992;55:486-90.
68. Kumar PP, Patil AA, Leibrock LG, Chu WK, Syh J, McCaul GR, et al. Brachytherapy: a viable alternative in the management of basal meningiomas. Neurosurgery 1991;29: 676-80.
69. Grunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, Russell CA, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 1991;74:861-6.